The genetic mechanisms underlying carbapenem resistance, one of the biggest therapeutic challenges in the treatment of antimicrobial-resistant infections, include increased upregulation of efflux pumps, decreased uptake by altered expression/loss of porin function, and acquisition of hydrolytic enzymes—carbapenemases9. This evidence concerns the gene VDAC1 and infection.